Jefferson University Hospitals

Provider Profile

Russell J. Schilder, MD

Russell J. Schilder, MD

Jefferson University Physician

Academic Title: Professor
Director, Medical Gynecologic Oncology Program

Specialties
Medical Oncology
Medical Oncology - Gynecologic Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697
Abington
1200 Old York Road
1 Widener - AMH
Abington PA 19001
Phone: (215) 885-0220
Fax: (215) 876-0740

Medical Services

Years in Practice

29

Board Certifications

  • Medical Oncology
  • Hematology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2008,2017,2009,2010,2011,2018

Notes

Dr. Schilder specializes in Cervical, Endometrial, Ovarian and Uterine Cancer.

Education

  • University of Miami School of Medicine, Medical School

Internship

  • Temple University Hospital

Residency

  • Temple University Hospital

Fellowship

  • Temple University Hospital

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amer Assoc Retired Persons (AARP)
  • AmeriHealth
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Blue Cross/Blue Shield of Delaware
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Delaware Blue Cross/Blue Shield
  • Devon
  • Empire BC/BS
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medallion of New Jersey
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • NJ Plus
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Ovarian Cancer: New Targets and Future Directions

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer

APhase i study of the SMAC-mimetic birinapant in adults with refractory solid tumorsor lymphoma

Hereditary ovarian cancer: Not only BRCA 1 and 2 Genes

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion

Refractory fallopian tube carcinoma - Current perspectives in pathogenesis and management

Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study

Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report

Personalized medicine and targeted therapy of gynecologic cancers

A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study